Kemin Industries has announced that the U.S. Patent and Trademark Office has granted the US 10,912,794 patent on the beta 1, 3 glucan for treating inflammation in the intestine and modulating human immune function. The patent approval comes after the US 9,574,217 patent issued to Kemin for the beta-glucan immune modulation which used algae from Euglena gracilis, ATCC PTA-123017. Dr. Geoff Horst, R&D Leader of Kemin Industries as well as Founder and Inventor of the proprietary Euglena gracilis, stated, “After years of research, we have found that certain species and strains of algae possess the ideal composition of bioactive ingredients and essential nutrients that could benefit human health. In particular, the Kemin proprietary strain of Euglena gracilis has shown especially robust immune support stemming from its high content of beta 1,3 glucan.”
Read more here.